Clinical Trial Update: FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) [Phase 1]

View source ↗

Summary

Phase 1 FT522-101 study evaluating FT522 in combination with Rituximab for relapsed/refractory B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• FT522
• Rituximab (rituximab)

Snippet

Sponsor: Fate Therapeutics | Conditions: Relapsed/Refractory B-Cell Lymphoma | Phase 1 | Status: COMPLETED